NDC 0781-2616-13 - Rivastigmine Tartrate
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0781-2616
- Requested NDC
- 0781-2616-13
- Package NDCs from labels
- 0781-2616-60, 0781-2616-13
- Manufacturer
- Sandoz Inc | Novartis Pharmaceuticals Corporation
- Effective date
- 2013-10-01
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| Rivastigmine Tartrate - Sandoz Inc | Novartis Pharmaceuticals Corporation | Sandoz Inc | Novartis Pharmaceuticals Corporation | 2013-10-01 | HUMAN PRESCRIPTION DRUG LABEL |
| National Council for Prescription Drug Programs indexing - billing unit | National Council for Prescription Drug Programs | 2012-07-24 | Indexing - Billing Unit |
FDA-Initiated Inactive NDC Indexing#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0781-2616-13 | EA - Each | 0781-2616 | b8f0d92d-d8b0-4954-ac28-14bbfab52aaa | 1 | 2012-07-24 |
| 0781-2616-60 | EA - Each | 0781-2616 | ae78d0ef-8516-4521-a211-dcdb46f98f34 | 1 | 2012-07-24 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| RIVASTIGMINE TARTRATE | ACTIVE INGREDIENT | 9IY2357JPE | RIVASTIGMINE TARTRATE CAPSULE [SANDOZ INC] | 2 | |
| RIVASTIGMINE | ACTIVE MOIETY | PKI06M3IW0 | RIVASTIGMINE TARTRATE CAPSULE [SANDOZ INC] | 2 | |
| CELLULOSE, MICROCRYSTALLINE | INACTIVE INGREDIENT | OP1R32D61U | RIVASTIGMINE TARTRATE CAPSULE [SANDOZ INC] | 2 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | RIVASTIGMINE TARTRATE CAPSULE [SANDOZ INC] | 2 | |
| FERRIC OXIDE YELLOW | INACTIVE INGREDIENT | EX438O2MRT | RIVASTIGMINE TARTRATE CAPSULE [SANDOZ INC] | 2 | |
| GELATIN | INACTIVE INGREDIENT | 2G86QN327L | RIVASTIGMINE TARTRATE CAPSULE [SANDOZ INC] | 2 | |
| HYPROMELLOSES | INACTIVE INGREDIENT | 3NXW29V3WO | RIVASTIGMINE TARTRATE CAPSULE [SANDOZ INC] | 2 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | RIVASTIGMINE TARTRATE CAPSULE [SANDOZ INC] | 2 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | RIVASTIGMINE TARTRATE CAPSULE [SANDOZ INC] | 2 | |
| TITANIUM DIOXIDE | INACTIVE INGREDIENT | 15FIX9V2JP | RIVASTIGMINE TARTRATE CAPSULE [SANDOZ INC] | 2 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.